Euro vs US Dollar

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

VIRX Viracta Therapeutics Inc

0,807

-0,0031 (-0,38%)

Nach Börsenschluss

Zuletzt aktualisiert: 23:59:00

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Viracta Therapeutics Charts.

Viracta Therapeutics (NASDAQ:VIRX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Viracta Therapeutics Charts.

News Viracta Therapeutics Inc

Viracta Therapeutics Announces New Employment Inducement Grants
Freitag 17 Mai 2024 (3 Stunden vor) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Donnerstag 16 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities
Donnerstag 16 Mai 2024 (1 Tag vor) • Edgar (US Regulatory)

Form 8-K - Current report
Dienstag 14 Mai 2024 (3 Tage vor) • Edgar (US Regulatory)

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer
Dienstag 14 Mai 2024 (4 Tage vor) • GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Form 8-K - Current report
Donnerstag 9 Mai 2024 (1 Woche vor) • Edgar (US Regulatory)

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Donnerstag 9 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Dienstag 7 Mai 2024 (1 Woche vor) • GlobeNewswire Inc.

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
Montag 15 April 2024 (1 Monat vor) • GlobeNewswire Inc.

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
Montag 1 April 2024 (2 Monate vor) • GlobeNewswire Inc.

Form S-8 - Securities to be offered to employees in employee benefit plans
Donnerstag 7 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Viracta Therapeutics Inc News-Artikel

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen